search
Back to results

Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery

Primary Purpose

Intrauterine Adhesions

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Uterine application of amnion membrane
Foley balloon
Femoston
Sponsored by
Capital Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Intrauterine Adhesions focused on measuring Intrauterine adhesions, Asherman Syndrome, Amnion graft

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • patients scheduled for adhesiolysis of intrauterine adhesions
  • patients willing to undergo followed hysteroscopy about 4 and 12 weeks after the surgery to assess the reformation of intrauterine adhesions.
  • Written, informed consent obtained.

Exclusion Criteria:

  • ongoing pregnancy
  • Peroperative fever or infections
  • Malignancy
  • Precious pelvic inflammatory disease
  • Uterine fibroid (>3cm size)
  • endometriosis
  • Contraindications for anesthesia
  • Not able to read and/or understand informed consent.

Sites / Locations

  • Fu Xing Hospital, Capital Medical University
  • Fu Xing Hospital, Capital Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

amnion graft in severe IUA

non-amnion graft in severe IUA

Arm Description

patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.

patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.

Outcomes

Primary Outcome Measures

safety of intrauterine application of amnion membrane
patients treated by amnion membrane following their hysteroscopic procedure were followed for immediate and late adverse effect: fever, abnormal vaginal discharge, pelvic pain, increased intrauterine adhesion formation upon follow up and changes in menstrual pattern.

Secondary Outcome Measures

efficacy of intrauterine application of amnion graft in reducing adhesion formation following hysteroscopic adhesiolysis.
intrauterine adhesions were assessed and graded according to the American Fertility Society (AFS) score upon hysteroscopy follow up 4 and 12 weeks following initial treatment.

Full Information

First Posted
May 2, 2014
Last Updated
October 20, 2014
Sponsor
Capital Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT02132104
Brief Title
Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery
Official Title
Amnion Graft for Preventing Intrauterine Adhesions Following Hysteroscopic Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Unknown status
Study Start Date
November 2014 (undefined)
Primary Completion Date
August 2016 (Anticipated)
Study Completion Date
November 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Capital Medical University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate whether human amnion graft reduces the reformation of severe intrauterine adhesions (IUA) following hysteroscopic adhesiolysis.
Detailed Description
Background IUA is a consequence of trauma to the endometrium, producing partial or complete obliteration in the uterine cavity and/or the cervical canal, resulting in conditions such as menstrual abnormalities, infertility, and recurrent pregnancy loss. The outcome of hysteroscopic adhesiolysis for IUA is significantly affected by recurrence of intrauterine adhesions. The IUA research should be directed toward reduction of adhesion reformation with a view to improve outcome. The reformation of intrauterine adhesions appears to be directly related to the severity of the adhesions. It has been reported that the recurrence rate for intrauterine adhesions ranges from 3.1% to 23.5% among all cases of intrauterine adhesions and from 20% to 62.5% in those with severe adhesions. In this study, considering the high recurrent rate in severe IUA, investigator will focus on severe IUA cases. Up to now several strategies are commonly employed by various investigators after division of intrauterine adhesions: Physical barriers have been used to promote regeneration of the endometrium and prevention of adhesions. The physical barriers include an intrauterine device (IUD), a Foley catheter, a number of modifications of hyaluronic acid and Auto-cross-linked hyaluronic acid gel. Hormonal treatment has been used to promote regeneration of the endometrium. Antibiotic therapy has been used to prevent infection which is a potent trigger for adhesion formation/reformation. Various medications have been described to increase vascular flow to endometrium, such as asprin, nitroglycerine and sildenafil citrate. There is published data (Amer et al, 2010), which based on a plot prospective, randomised, comparative study that grafting of either fresh or dried amnion is a promising adjunctive procedure for decreasing recurrence of adhesions and encouraging endometrial regeneration after hysteroscopic lysis of severe intrauterine adhesions. However, the study had a small number of patients, the valid conclusion can not be drawn. In this study, the aim is to compare the safety and the efficacy of insertion of intrauterine balloon + hormonal treatment with or without grafting amnion to prevent intrauterine adhesion formation/reformation following division of intrauterine adhesions. Study Design Patients with severe IUA are enrolled according to the classification of intrauterine adhesion by American Fertility Society. 208 patients with severe IUA were chosen at random and divided equally into those who received amnion graft, following hysteroscopic adhesiolysis (treatment groups) and to those who did not receive the amnion graft (control groups). Intervention Following hysteroscopic adhesiolysis, patients will be randomised to have a Foley balloon with or without amnion graft into the uterine cavity. Hormones therapy has been used after surgical treatment both in treatment groups and control groups. A second look and a third look hysteroscopy will be performed about 4 and 12 weeks after the initial operative hysteroscopy. The amount of adhesions, if any, during the initial and reexamine hysteroscopies will be scored. Power calculation The investigators' retrospective pilot study data showed that the recurrent rate of severe IUA is around 30% in amnion treatment groups, and around 47.5% in control groups. According to these data, investigators calculated the sample sizes of this study by using Cochran-Mantel-Haenszel test with software PASS 11. Investigators will recruit 104 patients in each group. Group sample sizes of 104 in group one and 104 in group two achieve 85% power to detect a difference between the group proportions of -0.2000. The group two proportion is 0.5000. The group one proportion is assumed to be 0.5000 under the null hypothesis and 0.3000 under the alternative hypothesis. The test statistic used is the two-sided Z test (unpooled). The significance level of the test was targeted at 0.0500. The significance level actually achieved by this design is not available. Statistics Safety and efficacy were evaluated by software NCSS-PASS, using Two Independent Proportions (Non-Null Case) Power Analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrauterine Adhesions
Keywords
Intrauterine adhesions, Asherman Syndrome, Amnion graft

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
208 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
amnion graft in severe IUA
Arm Type
Experimental
Arm Description
patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
Arm Title
non-amnion graft in severe IUA
Arm Type
Sham Comparator
Arm Description
patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
Intervention Type
Procedure
Intervention Name(s)
Uterine application of amnion membrane
Other Intervention Name(s)
Human amnion membrane
Intervention Description
Uterine application of amnion membrane following hysteroscopic adhesiolysis.
Intervention Type
Device
Intervention Name(s)
Foley balloon
Intervention Description
Uterine application of Foley balloon
Intervention Type
Drug
Intervention Name(s)
Femoston
Other Intervention Name(s)
Hormones
Intervention Description
Hormones treatment after surgery.
Primary Outcome Measure Information:
Title
safety of intrauterine application of amnion membrane
Description
patients treated by amnion membrane following their hysteroscopic procedure were followed for immediate and late adverse effect: fever, abnormal vaginal discharge, pelvic pain, increased intrauterine adhesion formation upon follow up and changes in menstrual pattern.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
efficacy of intrauterine application of amnion graft in reducing adhesion formation following hysteroscopic adhesiolysis.
Description
intrauterine adhesions were assessed and graded according to the American Fertility Society (AFS) score upon hysteroscopy follow up 4 and 12 weeks following initial treatment.
Time Frame
3 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients scheduled for adhesiolysis of intrauterine adhesions patients willing to undergo followed hysteroscopy about 4 and 12 weeks after the surgery to assess the reformation of intrauterine adhesions. Written, informed consent obtained. Exclusion Criteria: ongoing pregnancy Peroperative fever or infections Malignancy Precious pelvic inflammatory disease Uterine fibroid (>3cm size) endometriosis Contraindications for anesthesia Not able to read and/or understand informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xuebing Peng, MD
Phone
008613901297392
Email
peng_xue_bing@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
TC Li, PhD
Organizational Affiliation
Hysteroscopic Center, Fu Xing Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Xuebing Peng, MD
Organizational Affiliation
Hysteroscopic Center, Fu Xing Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Enlan Xia, MD
Organizational Affiliation
Hysteroscopic Center, Fu Xing Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Fu Xing Hospital, Capital Medical University
City
Beijing
ZIP/Postal Code
100038
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shanshan Zheng
Phone
0086 10 88062032
Email
fxyykjk@sina.com
First Name & Middle Initial & Last Name & Degree
Qin Zhong
Phone
0086 10 88062944
Email
fxyykjk@sina.com
First Name & Middle Initial & Last Name & Degree
Xuebing Peng, MD
First Name & Middle Initial & Last Name & Degree
TC Li, PhD
First Name & Middle Initial & Last Name & Degree
Xiaoxia Peng, PhD
Facility Name
Fu Xing Hospital, Capital Medical University
City
Beijing
ZIP/Postal Code
100038
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shanshan Zheng
Phone
0086 10 88062032
Email
fxyykjk@sina.com
First Name & Middle Initial & Last Name & Degree
Qin Zhong
Phone
008610 88062944
Email
fxyykjk@sina.com
First Name & Middle Initial & Last Name & Degree
Xuebing Peng, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
18406834
Citation
Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril. 2008 Apr;89(4):759-79. doi: 10.1016/j.fertnstert.2008.02.096.
Results Reference
background
PubMed Identifier
20576472
Citation
Amer MI, Abd-El-Maeboud KH, Abdelfatah I, Salama FA, Abdallah AS. Human amnion as a temporary biologic barrier after hysteroscopic lysis of severe intrauterine adhesions: pilot study. J Minim Invasive Gynecol. 2010 Sep-Oct;17(5):605-11. doi: 10.1016/j.jmig.2010.03.019. Epub 2010 Jun 23.
Results Reference
background
PubMed Identifier
17100817
Citation
Amer MI, Abd-El-Maeboud KH. Amnion graft following hysteroscopic lysis of intrauterine adhesions. J Obstet Gynaecol Res. 2006 Dec;32(6):559-66. doi: 10.1111/j.1447-0756.2006.00454.x.
Results Reference
background
PubMed Identifier
3371491
Citation
The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, mullerian anomalies and intrauterine adhesions. Fertil Steril. 1988 Jun;49(6):944-55. doi: 10.1016/s0015-0282(16)59942-7. No abstract available.
Results Reference
background

Learn more about this trial

Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery

We'll reach out to this number within 24 hrs